<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15035">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00224289</url>
  </required_header>
  <id_info>
    <org_study_id>27390</org_study_id>
    <nct_id>NCT00224289</nct_id>
  </id_info>
  <brief_title>Effect of Age on Latanoprost 0.005% in Patients With Glaucoma</brief_title>
  <official_title>Effect of Age on Efficacy and Response Time of Latanoprost 0.005% in Patients With Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Latanoprost is a commonly used treatment for glaucoma. Because of its mechanism of action,
      it is plausible that the age of a patient using the medication may affect its efficacy and
      time of onset.

      We are going to study the effectiveness of Latanoprost in people of different ages, to see
      if it changes based on the age of the patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Latanoprost is a topical ocular hypotensive medication with a well established safety and
      efficacy profile. Its effect is mediated by an increase in uveoscleral outflow, due to
      enzymatic degradation of the extracellular matrix within the ciliary muscle. Since the
      amount of extracellular matrix within the human eye increases with age, and uveoscleral
      outflow decreases with age, it would be expected that there should be a difference in the
      efficacy of latanoprost in patients of different ages. This has not been demonstrated in
      studies assessing the overall effect of latanoprost across adult age groups using
      multivariate analysis. (Camras CB et al, 1996).

      However, a difference in timing of onset of drug effect may get overlooked in clinical
      studies and in clinical practice as well, as patients tend to be seen from two to eight
      weeks after initiation of treatment, by which time any differences in response time may have
      already occurred and leveled off.

      To our knowledge, there are no studies specifically looking at the timing of onset of drug
      effect of latanoprost in different age groups. Because of the theoretical plausibility of
      this effect based on the mechanism of action of latanoprost, this represents an opportunity
      to further elucidate the characteristics of this medication in a manner which has clinical
      and scientific relevance.

      Our aim is thus to determine if there is a difference in timing of onset of the ocular
      hypotensive effect of latanoprost in glaucoma patients of different age groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pre-Treatment IOP (Intraocular Pressure)</measure>
    <time_frame>At baseline (before treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects applied topical latanoprost at bedtime for 8 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Treatment IOP (Intraocular Pressure)</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects applied topical latanoprost at bedtime for 8 weeks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will be taking Latanoprost; This study compares efficacy within age groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 0.005%</intervention_name>
    <description>Latanoprost 0.005% ophthalmic solution QHS 8 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xalatan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of open angle glaucoma,

          -  pseudoexfoliation glaucoma, pigmentary glaucoma or ocular hypertension in one or both
             eyes;

          -  IOP above their target pressure as determined by a glaucoma specialist;

          -  willingness to participate in the study.

        Exclusion Criteria:

          -  hypersensitivity to any of the components of the treatment medication;

          -  previous use of topical prostaglandins;

          -  documented ocular infection or intraocular inflammation within the past year;

          -  previous filtering surgery or complicated cataract surgery;

          -  active corneal disease;

          -  presence of cystoid macular edema;

          -  laser trabeculoplasty or any other ocular laser procedure within the past three
             months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Shields, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Eye Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 9, 2012</lastchanged_date>
  <firstreceived_date>September 16, 2005</firstreceived_date>
  <firstreceived_results_date>November 9, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Latanoprost</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Intraocular pressure</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Topical Latanoprost</title>
          <description>All participants will be taking Latanoprost; This study compares efficacy within age groups.
Latanoprost 0.005% : Latanoprost 0.005% ophthalmic solution QHS 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topical Latanoprost</title>
          <description>All participants will be taking Latanoprost; This study compares efficacy within age groups.
Latanoprost 0.005% : Latanoprost 0.005% ophthalmic solution QHS 8 weeks</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61.6" spread="12.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-Treatment IOP (Intraocular Pressure)</title>
        <description>Subjects applied topical latanoprost at bedtime for 8 weeks</description>
        <time_frame>At baseline (before treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Topical Latanoprost</title>
            <description>All participants will be taking Latanoprost; This study compares efficacy within age groups.
Latanoprost 0.005% : Latanoprost 0.005% ophthalmic solution QHS 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pre-Treatment IOP (Intraocular Pressure)</title>
            <description>Subjects applied topical latanoprost at bedtime for 8 weeks</description>
            <units>mm Hg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21.8" spread="6.28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-Treatment IOP (Intraocular Pressure)</title>
        <description>Subjects applied topical latanoprost at bedtime for 8 weeks</description>
        <time_frame>8 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Topical Latanoprost</title>
            <description>All participants will be taking Latanoprost; This study compares efficacy within age groups.
Latanoprost 0.005% : Latanoprost 0.005% ophthalmic solution QHS 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Post-Treatment IOP (Intraocular Pressure)</title>
            <description>Subjects applied topical latanoprost at bedtime for 8 weeks</description>
            <units>mm Hg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18.3" spread="5.36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event information was collected for 8 weeks per subject. The subjects received the study medication for 8 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Topical Latanoprost</title>
          <description>All participants will be taking Latanoprost; This study compares efficacy within age groups.
Latanoprost 0.005% : Latanoprost 0.005% ophthalmic solution QHS 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Red Eye w/ Foreign Body Sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Eye Tearing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bruce Shields, MD</name_or_title>
      <organization>Principal Investigator</organization>
      <phone>203-785-6288</phone>
      <email>bruce.shields@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
